University of Texas Medical Branch (UTMB), 2060 Space Park Drive, Suite 208, Nassau Bay, TX 77058, USA.
Adv Ther. 2011 Sep;28(9):748-60. doi: 10.1007/s12325-011-0058-5. Epub 2011 Aug 31.
Acute gouty arthritis is an inflammatory response triggered by the release of monosodium urate crystal deposits into the joint space. The disease is associated with debilitating clinical symptoms and functional impairments as well as adverse economic and quality-of-life burdens. Because gouty arthritis is typically diagnosed and managed in the primary care setting, clinicians require a thorough knowledge of the presenting clinical features, risk factors, differential diagnoses, and treatment options for appropriate management. Although generally effective, the use of currently available therapies to control gouty arthritis is challenging because many medications used to treat comorbidities can exacerbate gouty arthritis and because current agents are associated with a number of adverse events, contraindications, or both. Based on an understanding of the underlying inflammatory pathogenesis of gouty arthritis, several new agents are being developed that may provide improved efficacy.
急性痛风性关节炎是由单钠尿酸盐晶体沉积在关节腔内引发的炎症反应。该疾病与严重的临床症状和功能障碍以及不良的经济和生活质量负担有关。由于痛风性关节炎通常在初级保健环境中进行诊断和管理，因此临床医生需要全面了解其临床表现、风险因素、鉴别诊断和治疗选择，以便进行适当的管理。尽管目前的治疗方法通常有效，但控制痛风性关节炎的治疗方法具有挑战性，因为许多用于治疗合并症的药物会加重痛风性关节炎，而且目前的药物还会引起许多不良反应、禁忌症或两者兼有。基于对痛风性关节炎炎症发病机制的理解，正在开发几种新的药物，它们可能会提供更好的疗效。
